Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | PAK4 | O96013 | 3/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | WEE1 | P30291 | 3/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13896209 | 0.92 | MKNK1 (0.67) | MKNK1EGFRCDC7HTR2CKDR | |
| SCHEMBL13896565 | 0.85 | PLK4 (0.61) | EGFRHTR2CPAK4PLK4HTR2A | |
| SCHEMBL13896210 | 0.84 | EGFR (0.68) | MKNK1EGFRCDC7HTR2CKDR | |
| SCHEMBL4267261 | 0.83 | KDR (0.64) | MKNK1EGFRCDC7HTR2CKDR | |
| SCHEMBL3582538 | 0.78 | ULK1 (0.66) | PAK4AURKAULK1 | |
| SCHEMBL4259513 | 0.77 | EGFR (0.49) | MKNK1EGFRCDC7HTR2CKDR | |
| SCHEMBL3579380 | 0.75 | ULK1 (0.62) | CDC7HTR2CKDRPAK4HTR2A | |
| SCHEMBL13896564 | 0.75 | PLK4 (0.52) | MKNK1HTR2CPAK4PLK4HTR2A | |
| SCHEMBL13079395 | 0.75 | HTR2A (0.63) | HTR2CPAK4PLK4HTR2AJAK3 | |
| SCHEMBL3590277 | 0.74 | NPY5R (0.67) | KDRPAK4ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | disclosed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | DCK, CDK2, DTYMK | MKNK1 135/4885EGFR 1356/4885CDC7 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.